EC Pulmonology and Respiratory Medicine

Short Communication Volume 14 Issue 2 - 2025

Biologics Novel Therapy in Advanced COPD

Braden Schipp1* and Raghav Gupta2

1Assistant Professor (Former), Laboratory of Lung Inflammation, Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, United States

2Assistant Professor (Former), Laboratory of Lung Inflammation, Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, United States

*Corresponding Author: Braden Schipp, Department of Pulmonary and Critical Care, Deaconess Health System, United States.
Received: December 12, 2024; Published:January 11, 2025



Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory condition which causes critical health concerns and along with socioeconomic burden. Even with the maximum inhaled therapy, oral anti-inflammatory, oxygen, noninvasive ventilation, and pulmonary rehabilitation COPD patients continue to have exacerbations leading to significant impairment of quality of life [1].

  1. Dey S., et al. “Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities”. American Journal of Physiology-Lung Cellular and Molecular Physiology1 (2022): L64-L83.
  2. Aldonyte R., et al. “Novel aspects of pathogenesis and regeneration mechanisms in COPD”. International Journal of Chronic Obstructive Pulmonary Disease1 (2015): 995-1013.
  3. Guo P., et al. “Pathological mechanism and targeted drugs of COPD”. International Journal of Chronic Obstructive Pulmonary Disease 17 (2022): 1565-1575.
  4. Spurzem JR and Rennard SI. “Pathogenesis of COPD”. Seminars in Respiratory and Critical Care Medicine2 (2005): 142-153.
  5. Barnes PJ. “Oxidative stress-based therapeutics in COPD”. Redox Biology 33 (2020): 101544.
  6. Yang IA., et al. “Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment”. The Lancet Respiratory Medicine5 (2022): 497-511.
  7. Izquierdo Alonso JL. “Perfil clínico del roflumilast”. Archivos de Bronconeumología10 (2010): 25-32.
  8. Ambedkar Kumar Yadav., et al. “Current perspectives on biological therapy for COPD”. COPD: Journal of Chronic Obstructive Pulmonary Disease1 (2023): 197-209.
  9. Narendra DK and Hanania NA. “Targeting IL-5 in COPD”. International Journal of Chronic Obstructive Pulmonary Disease 14 (2019): 1045-1051.
  10. Doyle AD., et al. “Eosinophil-derived IL-13 promotes emphysema”. European Respiratory Journal5 (2019): 1801291.
  11. Zeng X., et al. “Association between TNF-α -308 G/A polymorphism and COPD susceptibility: a meta-analysis update”. International Journal of Chronic Obstructive Pulmonary Disease 11 (2016): 1367-1379.
  12. Bhatt SP., et al. “Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts”. New England Journal of Medicine3 (2023): 205-214.
  13. Christenson SA. “COPD phenotyping”. Respiratory Care7 (2023): 871-880.
  14. Brightling C and Greening N. “Airway inflammation in COPD: progress to precision medicine”. European Respiratory Journal 2 (2019): 1900651.
  15. Raby KL., et al. “Mechanisms of airway epithelial injury and abnormal repair in asthma and COPD”. Frontiers in Immunology 14 (2023): 1201658.
  16. Kersul AL and Cosio BG. “Biologics in COPD”. Open Respiratory Archives2 (2024): 100306.

Braden Schipp and Raghav Gupta. "Biologics Novel Therapy in Advanced COPD". EC Pulmonology and Respiratory Medicine  14.2 (2025): 01-03.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net